The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 174%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (16 analysts) rates it strong buy, with a mean price target of $65.
BrightSpring Health Services Inc BTSG
Clears the common standard
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · BrightSpring Health Services, Inc.
read at $60.23
BrightSpring Health Services Inc holds its Distribution at $60.23.
- PHPhase · the trend structure carries the Distribution label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 4 days |
| Price | $60.23 |
| Valuation | 53.78 trailing · 26.44 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.88 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 23.00% |
| Profit margin | 2.55% |
| Debt to equity | 116.01 |
| Analyst consensus | Strong Buy · 17 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✗ DOES NOT PASS
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is 42.2% of its assets, above the one-third ceiling the screen allows. Against market value it is 19.0%, under the 30% line the market-value standard uses — so that standard clears it. Divergent
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 16.8% of assets, under the 49% limit. Pass
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Home Care Platform Priced Beyond Its Value
Picture an elderly patient receiving pharmacy deliveries and nurse visits at home. BrightSpring handles those daily touches through its pharmacy and provider arms, yet the shares sit at $70.69 against a fair value of $63.50. That leaves a negative margin of safety and an opportunity rating of none, so we pass.
Revenue is rising 26 percent, yet the business earns just a 2 percent profit margin and a 9 percent return on equity. The forward multiple of 33.1 times earnings looks rich for a narrow-moat operator in a competitive field, even with a clean ethical screen and bullish analyst targets.
Narrow competitive protection and thin returns leave little room for disappointment if reimbursement rates tighten or labour costs rise. The current price already bakes in strong growth that the numbers have yet to deliver at scale. Analysis, not advice.
| Forward P/E | 26.4x fairly priced for its growth rate |
| Trailing P/E | 53.8x expensive — the price assumes strong growth ahead |
| Revenue growth | 23.0% strong top-line growth |
| Profit margin | 2.5% barely profitable |
| Return on equity | 13.0% a solid return on shareholder capital |
| Debt to equity | 1.16 a meaningful debt load worth watching |
| Current ratio | 1.59 healthy short-term liquidity |
| Beta | 1.88 much more volatile than the market |
| Market cap | $11.9B |
| Employees | 23,500 |
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in BTSG's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 174%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (16 analysts) rates it strong buy, with a mean price target of $65.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $55.07 | +10.6% | · | $1,106 | +10.6% |
| 2 months | $45.33 | +34.4% | · | $1,344 | +34.4% |
| 3 months | $38.64 | +57.6% | · | $1,576 | +57.6% |
| 6 months | $35.90 | +69.6% | · | $1,696 | +69.6% |
| 1 year | $22.24 | +173.8% | · | $2,738 | +173.8% |
| 2 years | $11.21 | +443.3% | · | $5,433 | +443.3% |
Historical returns from market close data. Past performance does not guarantee future results.